Treatment of High-Risk Smoldering Myeloma

Multiple Myeloma (MM) is almost always preceded by a precursor disease state [1]. Smoldering myeloma (SMM) is a precursor disease defined by clinical and histopathological features (absence of myeloma defining biomarkers or end organ damage and bone marrow plasma cells (BMPC) ≥10% or monoclonal protein ≥3 g/dL). Traditionally, SMM is approached with careful routine monitoring. First, I must disclose that my general practice is to treat SMM patients within the context of clinical trials. For high-risk SMM patients not eligible for clinical trials, I continue to observ e patients until they meet updated International Myeloma Working Group (IMWG) MM criteria [2].
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research